Patients’ medical treatment history was typical for IBD, with CD patients statistically significantly more often exposed to antimetabolites, anti-TNFα, and anti-IL-12/23 biologics, compared with ulcerative colitis patients who were, in line with professional treatment guidelines, prescribed aminosalicylates, calcineurin inhibitors, and anti-integrins more often. Here, TNF is linked to inflammatory bowel disease.